Prevention and treatment options for mTOR inhibitor-associated stomatitis

2017 ◽  
Vol 15 (2) ◽  
pp. 74-81 ◽  
Author(s):  
Kelly Staves ◽  
Kavitha Ramchandran
Keyword(s):  
Mtor Inhibitor ◽  
Treatment Options ◽  
Prevention And Treatment

scholarly journals Prevalence of Metabolic Syndrome in Children and Adolescents with Type 1 Diabetes Mellitus and Possibilities of Prevention and Treatment: A Systematic Review

Nutrients ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1782
Author(s):  
Monika Grabia ◽  
Renata Markiewicz-Żukowska ◽  
Katarzyna Socha
Keyword(s):  
Systematic Review ◽  
Metabolic Syndrome ◽  
Type 1 Diabetes ◽  
Children And Adolescents ◽  
Treatment Options ◽  
Overweight And Obesity ◽  
Excess Body Weight ◽  
Healthy Population ◽  
Prevention And Treatment

Overweight and obesity are an increasingly common problem, not only among the healthy population, but also in adolescents with type 1 diabetes (T1DM). Excess body weight is related to many cardiometabolic complications as well as a high risk of metabolic syndrome (MetS). The purpose of this systematic review is to provide a concise and critical overview of the prevalence of MetS in children and adolescents with T1DM and, ultimately, to discuss prevention and treatment options. The study was conducted in accordance with PRISMA guidelines. This review shows that, apart from the growing percentage of overweight and obese children and adolescents with T1DM (on average 20.1% and 9.5%, respectively), the problem of the increasing incidence of MetS (range from 3.2 to 29.9%, depending on the criteria used) is one of the most important phenomena of our time. One of the methods of prevention and treatment is a combined approach: changing eating habits and lifestyle, but there are also reports about the beneficial effects of the gut microflora.

Chronic endometritis: prevention and treatment options

2021 ◽  
Vol 20 (4) ◽  
pp. 115-122
Author(s):  
Yu.E. Dobrokhotova ◽  
◽  
E.I. Borovkova ◽  
O.R. Nugumanova ◽  
◽  
...  
Keyword(s):  
Treatment Options ◽  
Empiric Therapy ◽  
Cytokine Therapy ◽  
Colony Stimulating Factor ◽  
Chronic Endometritis ◽  
Prevention And Treatment ◽  
Therapy Standards ◽  
Colonystimulating Factor ◽  
Prevention Methods ◽  
Stimulating Factor

This article is a review of publications devoted to the treatment of chronic endometritis and methods of its prevention. Methods of empiric therapy, standards of antibacterial therapy, and modern guidelines for treatment under development (colonystimulating factor, immunotherapy, amplipulse therapy) are presented. Key words: infertility, miscarriage, colony-stimulating factor, chronic endometritis, cytokine therapy

scholarly journals New Treatments for Renal Cell Carcinoma: Targeted Therapies

2009 ◽  
Vol 7 (6) ◽  
pp. 645-656 ◽  
Author(s):  
Philip J. Saylor ◽  
M. Dror Michaelson
Keyword(s):  
Renal Cell Carcinoma ◽  
Targeted Therapies ◽  
Mtor Inhibitor ◽  
Kinase Inhibitors ◽  
Clear Cell ◽  
Treatment Options ◽  
Line Treatment ◽  
Second Line ◽  
Targeted Agents ◽  
First Line

Systemic treatment options for advanced renal cell carcinoma (RCC) have expanded considerably with the development of targeted therapies. Clear cell RCC commonly features mutation or inactivation of the von Hippel-Lindau gene and resultant overexpression of vascular endothelial growth factor (VEGF). The first drug to validate VEGF as a target in the treatment of clear cell RCC was the monoclonal antibody bevacizumab. Since then, anti-VEGF receptor therapy with multitargeted kinase inhibitors also has shown substantial efficacy. Sunitinib is now a standard first-line therapy for advanced disease and sorafenib is among the second-line treatment options. Other kinase inhibitors are in development. Mammalian target of rapamycin (mTOR) is a second validated therapeutic target as the mTOR inhibitor temsirolimus has been shown to prolong survival in first-line treatment of poor prognosis RCC of all histologies. Everolimus is an oral mTOR inhibitor and has been shown to prolong progression-free survival when used in second-line treatment. Non-clear cell and sarcomatoid RCC are both underrepresented in completed trials but are the subject of active research. Ongoing and planned studies will also evaluate the use of combinations of targeted agents, a strategy that is not advisable outside of clinical trials. Finally, postnephrectomy adjuvant treatment with targeted agents is not yet standard but is under investigation in phase III trials.

scholarly journals Ingredients Acting as a Physical Barrier for the Prevention and Treatment of the Rhinovirus Infection

2020 ◽  
Vol 10 (18) ◽  
pp. 6511
Author(s):  
Lisa-Marie Sittek ◽  
Thomas Michael Schmidts ◽  
Peggy Schlupp
Keyword(s):  
Xanthan Gum ◽  
Artificial Saliva ◽  
Treatment Options ◽  
Plaque Assay ◽  
Sodium Hyaluronate ◽  
Curative Effect ◽  
Cell Monolayers ◽  
Prevention And Treatment ◽  
The Common ◽  
First Time

Although the common cold, usually caused by human rhinoviruses, is responsible for enormous damage to the economy and health every year, there are hardly any treatment options or prophylaxis for rhinovirus infections. In this work, the potential of a hydrogel complex, based on polymers and an aqueous extract of Icelandic moss in isla® medic lozenges (Engelhard Arzneimittel, Niederdorfelden, Germany), and two other hydrogels (based on solely xanthan gum or sodium hyaluronate) are investigated for the first time in order to prevent and treat rhinovirus infections. By means of rheological investigations, we demonstrate that isla® medic and containing polymers cause artificial saliva to thicken. Additionally, we demonstrate that the thickening results in the formation of a physical diffusion barrier, which leads to a significant reduction in plaques in a preventive plaque assay with rhinovirus 14 (RV-14). Furthermore, it is shown in a curative plaque assay that the hydrogel complex also has a curative effect on rhinovirus infections in that it reduces the spread of the RV-14-infection on H1-HeLa cell monolayers. Overall, polymer-based hydrogels and related products, such as isla® medic, could contribute to the prevention and treatment of rhinovirus infections.

scholarly journals Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
T. C. Schneider ◽  
D. de Wit ◽  
T. P. Links ◽  
N. P. van Erp ◽  
J. J. M. van der Hoeven ◽  
...  
Keyword(s):  
Phase Ii ◽  
Mtor Inhibitor ◽  
Treatment Options ◽  
Plasma Concentrations ◽  
Progression Free Survival ◽  
Primary Objective ◽  
Medullary Thyroid ◽  
Beneficial Effects ◽  
Secondary Endpoints ◽  
High Level

Objective. Until recently, advanced medullary thyroid cancer (MTC) had few treatment options except surgery. The mTOR inhibitor everolimus has shown encouraging results in neuroendocrine tumors. As part of a prospective phase II study, we analyzed the safety and efficacy of everolimus in advanced MTC.Methods. Seven patients with per RECIST 1.1 documented advanced MTC were included and received everolimus 10 mg daily. The primary objective was determining treatment efficacy. Secondary endpoints included progression-free survival (PFS), overall survival (OS), toxicity, and pharmacokinetics (PK).Results. Median follow-up duration was 28 weeks (17–147). Five patients (71%) showed SD, of which 4 (57%) showed SD >24 weeks. Median PFS and OS were 33 (95%CI: 8–56) and 30 (95%CI: 15–45) weeks, respectively. Toxicity was predominantly grade 1/2 and included mucositis (43%), fatigue (43%), and hypertriglyceridemia (43%). Four MTCs harbored the somaticRETmutation c.2753T>C, p.Met918Thr. The best clinical response was seen in a MEN2A patient. PK characteristics were consistent with phase I data. One patient exhibited extensive toxicity accompanying elevated everolimus plasma concentrations.Conclusions. This study suggests that everolimus exerts clinically relevant antitumor activity in patients with advanced MTC. Given the high level of clinical benefit and the relatively low toxicity profile, further investigation of everolimus in these patients is warranted.

Fixed Sagittal Plane Deformity: Causes, Prevention, and Treatment Options

2011 ◽  
Vol 23 (2) ◽  
pp. 135-141
Author(s):  
Ali Moshirfar ◽  
Frank F. Rand ◽  
Khaled M. Kebaish
Keyword(s):  
Sagittal Plane ◽  
Treatment Options ◽  
Prevention And Treatment ◽  
Plane Deformity

GOUT. TREATMENT OPTIONS MODERN AND ALTERNATIVE MEDICINE

Fitoterapia ◽  
2021 ◽  
Vol 1 (1) ◽  
pp. 16-20
Author(s):  
Y.A. Philippov ◽  
◽  
T.V. Evtushenko ◽  
Keyword(s):  
Treatment Options ◽  
Special Technique ◽  
Disease Development ◽  
Internal Organs ◽  
Alkaline Salt ◽  
Prevention And Treatment ◽  
Natural Remedies ◽  
Therapeutic Measures ◽  
Acute Attacks ◽  
Specific Diet

Keywords: Gout - Diatesis urica, uric acid, purine bases. The problem of prevention and treatment of gout for middle- aged and elderly people is a life issue. The implementation of the disease development preventing strategy is possible with the timely and systematic use of preventive and therapeutic measures, gout acute attacks prevention and disability prevention. Rational measures are: systematic individual exercise therapy, the use of rhodonic, sulfuric, mineral alkaline- salt baths, paraffin and shungite applications, magnetotherapy with the “Vitma-1” apparatus according to a special technique, natural remedies in the form of phyto-assemblies, phyto- and homeopathic preparations, compresses with mummy and a specific diet. The use of these methods contributes to the restoration of bone tissue damaged cells, tendons, and internal organs.

Sign in / Sign up

Export Citation Format

Share Document